InsiderTrades

Form 4 for APVO Aptevo Therapeutics Inc.

Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-02 · accession 0000950170-25-032187 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-03-04 2025-03-02+ APVO White Marvin L Pres, CEO, Dir M - OptEx — +14 55 +34% —
DM 2025-03-04 2025-03-02+ APVO White Marvin L Pres, CEO, Dir M - OptEx $0.00 -14 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-02 M A 8 — 49 D — — (F1) Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2 Common Common Stock 2025-03-03 M A 6 — 55 D — — (F1) Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
3 Derivative Restricted Stock Unit 2025-03-02 M D 8 $0.00 8 D — · — to — 8 Common Stock (F1) Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. (F2) On March 3, 2023, the reporting person was granted 38,750 (24 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024.
4 Derivative Restricted Stock Unit 2025-03-03 M D 6 $0.00 0 D — · — to — 6 Common Stock (F1) Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. (F3) On June 7, 2022, the reporting person was granted 28,750 (18 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023.